{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:46:06Z","timestamp":1776746766104,"version":"3.51.2"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2024JJ9570"],"award-info":[{"award-number":["2024JJ9570"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium\u2013glucose cotransporter 2 inhibitors (SGLT2i) have been shown to improve clinical outcomes in patients with heart failure; however, their efficacy and safety in patients with myocardial infarction, particularly when used in addition to conventional therapy, remain controversial. Therefore, this study aims to evaluate the effects of adding SGLT2i to conventional therapy on clinical outcomes in patients with myocardial infarction through a systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis to compare the effects of conventional therapy with or without SGLT2i on clinical outcomes in patients with myocardial infarction. PubMed, Web of Science, the Cochrane Library, and Embase were systematically searched.<\/jats:p>\n                    <jats:p>The primary outcome was the incidence of hospitalization for heart failure. Secondary outcomes included all-cause mortality, major adverse cardiovascular events (MACE), left ventricular ejection fraction (LVEF), N-terminal pro-B type natriuretic peptide (NT-proBNP), and low-density lipoprotein cholesterol (LDL-C). Safety outcomes comprised renal dysfunction, hepatic dysfunction, urinary tract infection, and glycemia-related adverse events. All analyses were conducted using a random-effects model. Prespecified subgroup analyses for the primary outcome were performed according to the presence or absence of type 2 diabetes mellitus, timing of SGLT2i initiation, and specific SGLT2i agent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This meta-analysis included 13 randomized controlled trials involving 22,238 patients with myocardial infarction. Compared with conventional therapy alone, treatment with SGLT-2i significantly reduced the incidence of hospitalization for heart failure (RR\u2009=\u20090.76, 95% CI 0.68\u20130.84,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.00001). For key secondary outcomes, the use of SGLT2i was not associated with all-cause mortality (RR\u2009=\u20090.87, 95% CI 0.75\u20131.01,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.06), but was associated with a significant reduction in the risk of major adverse cardiovascular events (MACE) (RR\u2009=\u20090.84, 95% CI 0.73\u20130.98,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03). However, no significant difference was observed between the two groups in cardiovascular mortality (RR\u2009=\u20090.87, 95% CI 0.61\u20131.24,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.44). In addition, SGLT2i combined with conventional therapy significantly improved left ventricular ejection fraction (MD\u2009=\u20093.45, 95% CI 0.67\u20136.24,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02) and significantly reduced NT-proBNP levels (MD\u2009=\u2009\u2212311.99, 95% CI \u2212666.00\u201315.23,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04). In terms of safety outcomes, the use of SGLT2i was associated with a reduced risk of renal dysfunction (RR\u2009=\u20090.77, 95% CI 0.66\u20130.89,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0006) and glycemia-related adverse events (RR\u2009=\u20090.56, 95% CI 0.40\u20130.80,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090. 001). No significant increase was observed in the risk of urinary tract infection (RR\u2009=\u20091.73, 95% CI 0.76\u20133.97,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.12;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.19) or hepatic dysfunction (RR\u2009=\u20092.46, 95% CI 0.86\u20136.98,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.09;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.49). Prespecified subgroup analyses showed that the treatment benefit for the primary outcome was generally consistent irrespective of the presence or absence of type 2 diabetes mellitus or the specific SGLT2i agent used.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this meta-analysis, the addition of SGLT2i to standard therapy following myocardial infarction was associated with a reduction in hospitalization for heart failure, as well as a lower incidence of renal dysfunction and glycemia-related adverse events. Furthermore, favorable effects of SGLT2i were observed in patients with MI irrespective of the presence or absence of type 2 diabetes mellitus or the specific SGLT2i agent used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>PROSPERO CRD420251129087.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1797628","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:22:15Z","timestamp":1776745335000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical effects of sodium\u2013glucose cotransporter 2 inhibitors combined with conventional therapy in myocardial infarction: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhipeng","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Lingchuan County Hospital of Traditional Chinese Medicine","place":["Jincheng, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinjun","family":"Dai","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Integrated Traditional Chinese and Western Medicine of Hunan University of Chinese Medicine","place":["Changsha, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianhang","family":"Jia","sequence":"additional","affiliation":[{"name":"Cardiovascular Surgery Department, Xi'an No.1 Hospital","place":["Xi'an, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Heping Hospital Affiliated to Changzhi Medical College","place":["Changzhi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Heping Hospital Affiliated to Changzhi Medical College","place":["Changzhi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengfei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Heping Hospital Affiliated to Changzhi Medical College","place":["Changzhi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Heping Hospital Affiliated to Changzhi Medical College","place":["Changzhi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Integrated Traditional Chinese and Western Medicine of Hunan University of Chinese Medicine","place":["Changsha, China"]},{"name":"Department of Hematology, Oncology, and Immunology, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa0908610","article-title":"Population trends in the incidence and outcomes of acute myocardial infarction","volume":"362","author":"Yeh","year":"2010","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","article-title":"American Heart Association Council on epidemiology and prevention statistics committee and stroke statistics subcommittee. 2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"149","author":"Martin","year":"2024","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.atherosclerosis.2019.06.899","article-title":"The prevalence and management of familial hypercholesterolemia in patients with acute coronary syndrome in the Polish tertiary centre: results from the TERCET registry with 19,781 individuals","volume":"288","author":"Dyrbu\u015b","year":"2019","journal-title":"Atherosclerosis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12872-023-03231-w","article-title":"The global prevalence of myocardial infarction: a systematic review and meta-analysis","volume":"23","author":"Salari","year":"2023","journal-title":"BMC Cardiovasc Disord"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1161\/CIRCULATIONAHA.120.046682","article-title":"Biomarkers enhance discrimination and prognosis of type 2 myocardial infarction","volume":"142","author":"Horiuchi","year":"2020","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jcin.2022.09.039","article-title":"Early invasive strategy based on the time of symptom onset of non-ST-segment elevation myocardial infarction","volume":"16","author":"Bae","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1093\/eurheartj\/ehae435","article-title":"Coronary artery disease management in older adults: revascularization and exercise training","volume":"45","author":"Pavasini","year":"2024","journal-title":"Eur Heart J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.jchf.2024.04.025","article-title":"Where are we with treatment and prevention of heart failure in patients post-myocardial infarction?","volume":"12","author":"Carberry","year":"2024","journal-title":"JACC Heart Fail"},{"key":"B9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium\u2013glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes Mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1136\/heartjnl-2020-318060","article-title":"Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure","volume":"107","author":"Joshi","year":"2021","journal-title":"Heart"},{"key":"B11","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/cvr\/cvae047","article-title":"SGLT2 Inhibitors: from glucose-lowering to cardiovascular benefits","volume":"120","author":"Preda","year":"2024","journal-title":"Cardiovasc Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1093\/eurheartj\/ehad389","article-title":"Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction","volume":"44","author":"Pandey","year":"2023","journal-title":"Eur Heart J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2514078","DOI":"10.1080\/07853890.2025.2514078","article-title":"Efficacy and safety of empagliflozin for the acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials","volume":"57","author":"Peng","year":"2025","journal-title":"Ann Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/ejhf.3184","article-title":"Dapagliflozin in patients with heart failure and previous myocardial infarction: a participant-level pooled analysis of DAPA-HF and DELIVER","volume":"26","author":"Peikert","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after acute myocardial infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"ED000142","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1093\/eurheartj\/ehac223","article-title":"Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies","volume":"43","author":"Frantz","year":"2022","journal-title":"Eur Heart J"},{"key":"B20","article-title":"Cochrane handbook for systematic reviews of interventions version 6.5.","author":"Higgins","year":"2023","journal-title":"Cochrane"},{"key":"B21","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Br Med J"},{"key":"B22","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"Br Med J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","article-title":"Empagliflozin reduced mortality and hospitalization for heart failure across the Spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial","volume":"139","author":"Fitchett","year":"2019","journal-title":"Circulation"},{"key":"B25","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12933-020-01127-z","article-title":"Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial","volume":"19","author":"Shimizu","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1002\/ehf2.13509","article-title":"Empagliflozin confers reno-protection in acute myocardial infarction and type 2 diabetes mellitus","volume":"8","author":"Mozawa","year":"2021","journal-title":"ESC Heart Fail"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.119.039996","article-title":"Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes Mellitus and previous myocardial infarction","volume":"139","author":"Furtado","year":"2019","journal-title":"Circulation"},{"key":"B28","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/ejhf.3560","article-title":"Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI)","volume":"27","author":"Carberry","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1093\/eurheartj\/ehac494","article-title":"Empagliflozin in acute myocardial infarction: the EMMY trial","volume":"43","author":"von Lewinski","year":"2022","journal-title":"Eur Heart J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"458","DOI":"10.15537\/smj.2022.43.5.20220018","article-title":"Effect of a low dose of empagliflozin on short-term outcomes in type 2 diabetics with acute coronary syndrome after percutaneous coronary intervention","volume":"43","author":"Adel","year":"2022","journal-title":"SMJ"},{"key":"B31","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s40256-024-00662-4","article-title":"Empagliflozin effects in patients with ST-elevation myocardial infarction undergoing primary PCI: the EMI-STEMI randomized clinical trial","volume":"24","author":"Khani","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"key":"B32","doi-asserted-by":"publisher","first-page":"ehae666.1417","DOI":"10.1093\/eurheartj\/ehae666.1417","article-title":"Impact of dapagliflozin on cardiometabolic outcomes after myocardial infarction according to baseline left ventricular ejection fraction: a DAPA-MI substudy","volume":"45","author":"Erlinge","year":"2024","journal-title":"Eur Heart J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1490316","DOI":"10.3389\/fcvm.2024.1490316","article-title":"Effects of dapagliflozin on heart rate variability, cardiac function, and short-term prognosis in early-onset post-myocardial infarction heart failure","volume":"11","author":"Zhou","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/j.hlc.2025.05.094","article-title":"iCARDIO alliance global implementation guidelines on heart failure 2025","volume":"34","author":"Chopra","year":"2025","journal-title":"Heart Lung Circ"},{"key":"B35","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jchf.2021.11.006","article-title":"Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: dELIVER trial","volume":"10","author":"Solomon","year":"2022","journal-title":"JACC Heart Fail"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/imj.14260","article-title":"Effects of empagliflozin treatment on cardiac function and structure in patients with type 2 diabetes: a cardiac magnetic resonance study","volume":"49","author":"Cohen","year":"2019","journal-title":"Intern Med J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1016\/j.jacc.2022.03.353","article-title":"Sodium glucose cotransporter-2 inhibition for acute myocardial infarction: JACC review topic of the week","volume":"79","author":"Udell","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3389\/fcvm.2019.00186","article-title":"SGLT2 inhibitors play a salutary role in heart failure via modulation of the mitochondrial function","volume":"6","author":"Maejima","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s10741-021-10096-8","article-title":"SGLT2 Inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism","volume":"27","author":"Wang","year":"2022","journal-title":"Heart Fail Rev"},{"key":"B40","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic na+ through inhibition of the cardiac na+\/H+ exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e007197","DOI":"10.1161\/CIRCHEARTFAILURE.120.007197","article-title":"Cardioprotective effects of sirtuin-1 and its downstream effectors: potential role in mediating the heart failure benefits of SGLT2 (sodium-glucose cotransporter 2) inhibitors","volume":"13","author":"Packer","year":"2020","journal-title":"Circ Heart Fail"},{"key":"B42","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1093\/cvr\/cvaa064","article-title":"Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress","volume":"117","author":"Packer","year":"2021","journal-title":"Cardiovasc Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12933-020-01048-x","article-title":"The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study","volume":"19","author":"Chen","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.cardfail.2021.07.003","article-title":"The potential roles of osmotic and nonosmotic sodium handling in mediating the effects of sodium-glucose cotransporter 2 inhibitors on heart failure","volume":"27","author":"Bjornstad","year":"2021","journal-title":"J Card Fail"},{"key":"B45","doi-asserted-by":"publisher","first-page":"8786","DOI":"10.3390\/ijms22168786","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on vascular cell function and arterial remodeling","volume":"22","author":"Durante","year":"2021","journal-title":"IJMS"},{"key":"B46","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/FJC.0000000000001659","article-title":"Comparing the efficacy of sodium-glucose cotransporter 2 inhibitors among nonolder and older patients: a systematic review and meta-analysis","volume":"85","author":"Yamashita","year":"2025","journal-title":"J Cardiovasc Pharmacol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1797628\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:22:16Z","timestamp":1776745336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1797628\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":46,"alternative-id":["10.3389\/fcvm.2026.1797628"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1797628","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"article-number":"1797628"}}